このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

BeiGene マネジメント

マネジメント基準チェック /24

BeiGene'sの CEO はJohn Oylerで、 Jan2010年に任命され、の在任期間は 14.42年です。の年間総報酬は$ 18.93Mで、 4.6%給与と95.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の3.44%を直接所有しており、その価値は$ 560.77M 。経営陣と取締役会の平均在任期間はそれぞれ2.7年と4.4年です。

主要情報

John Oyler

最高経営責任者

US$18.9m

報酬総額

CEO給与比率	4.6%
CEO在任期間	14.4yrs
CEOの所有権	3.4%
経営陣の平均在職期間	2.7yrs
取締役会の平均在任期間	4.4yrs

経営陣の近況

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

May 30

Recent updates

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

Jun 21

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

May 30

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

Apr 21

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

Mar 08

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Jan 31

CEO報酬分析

BeiGene の収益と比較して、John Oyler の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$784m
Dec 31 2023	US$19m	US$871k	-US$882m
Sep 30 2023	n/a	n/a	-US$959m
Jun 30 2023	n/a	n/a	-US$2b
Mar 31 2023	n/a	n/a	-US$2b
Dec 31 2022	US$18m	US$800k	-US$2b
Sep 30 2022	n/a	n/a	-US$2b
Jun 30 2022	n/a	n/a	-US$2b
Mar 31 2022	n/a	n/a	-US$2b
Dec 31 2021	US$17m	US$740k	-US$1b
Sep 30 2021	n/a	n/a	-US$1b
Jun 30 2021	n/a	n/a	-US$1b
Mar 31 2021	n/a	n/a	-US$1b
Dec 31 2020	US$14m	US$696k	-US$2b
Sep 30 2020	n/a	n/a	-US$2b
Jun 30 2020	n/a	n/a	-US$1b
Mar 31 2020	n/a	n/a	-US$1b
Dec 31 2019	US$13m	US$675k	-US$949m
Sep 30 2019	n/a	n/a	-US$829m
Jun 30 2019	n/a	n/a	-US$665m
Mar 31 2019	n/a	n/a	-US$737m
Dec 31 2018	US$28m	US$650k	-US$674m
Sep 30 2018	n/a	n/a	-US$505m
Jun 30 2018	n/a	n/a	-US$243m
Mar 31 2018	n/a	n/a	-US$147m
Dec 31 2017	US$10m	US$515k	-US$93m

報酬と市場: Johnの総報酬 ($USD 18.93M ) は、 US市場 ($USD 13.52M ) の同規模の企業の平均を上回っています。

報酬と収益: Johnの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

John Oyler (56 yo)

14.4yrs

在職期間

US$18,925,730

報酬

Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009....

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
John Oyler	Co-Founder	14.4yrs	US$18.93m	3.44% $ 560.8m
Xiaobin Wu	President & COO	6.1yrs	US$11.00m	0.060% $ 9.8m
Xiaodong Wang	Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder	14.4yrs	US$4.42m	0.77% $ 125.5m
Julia Wang	CFO & Principal Financial Officer	3yrs	US$6.07m	0.034% $ 5.5m
Chan Lee	General Counsel & Senior VP	1.9yrs	US$4.05m	0.020% $ 3.2m
Wang Lai	Global Head of R&D	no data	US$7.32m	0.13% $ 21.9m
Titus Ball	VP & Chief Accounting Officer	less than a year	データなし	データなし
Liza Heapes	Head of Investor Relations	no data	データなし	データなし
Yang Ji	Chief Compliance Officer	less than a year	データなし	データなし
Yan Qi	Senior VP & Head of Public Affairs - Greater China	3.4yrs	データなし	データなし
Jason Radford	Senior Vice President of Strategy & Corporate Development	1.3yrs	データなし	データなし
Mark Lanasa	Senior VP & Chief Medical Officer for Solid Tumors	2.3yrs	データなし	データなし

2.7yrs

平均在職期間

54.5yo

平均年齢

経験豊富な経営陣: BGNEの経営陣は経験豊富であると考えられます ( 2.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
John Oyler	Co-Founder	13.7yrs	US$18.93m	3.44% $ 560.8m
Xiaodong Wang	Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder	8.3yrs	US$4.42m	0.77% $ 125.5m
Steven Young	Acting Head of Medicinal Chemistry & Member of Scientific Advisory Board	3.2yrs	データなし	データなし
Michael Goller	Independent Non-Executive Director & Member of the Scientific Advisory Committee	9.2yrs	US$481.92k	0.0034% $ 559.0k
Donald Glazer	Independent Non-Executive Director	11.3yrs	US$480.80k	0.20% $ 32.4m
Corazon Sanders	Independent Non-Executive Director & Member of Scientific Advisory Committee	3.8yrs	US$501.55k	0.0022% $ 358.6k
Anthony Hooper	Independent Non-Executive Director	4.4yrs	US$513.15k	0.0027% $ 448.2k
Alessandro Riva	Co-Chairman of Scientific Advisory Committee & Independent Non-Executive Director	2.3yrs	US$491.67k	0.0022% $ 355.3k
Olivier Brandicourt	Independent Non-Executive Director	less than a year	データなし	0% $ 0
Ranjeev Krishana	Independent Lead Director	9.7yrs	US$487.05k	0.0034% $ 559.0k
Margaret Han Dugan	Member of Scientific Advisory Board & Independent Non-Executive Director	2.3yrs	US$510.55k	0.0022% $ 355.3k

4.4yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: BGNEの取締役会は経験豊富であると考えられます ( 4.4年の平均在任期間)。

BeiGene マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

BeiGene, Ltd., Annual General Meeting, Jun 05, 2024

Co-Founder recently sold US$7.5m worth of stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Beigene, Ltd. Announces Board Changes

Recent updates

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

First quarter 2024 earnings released: US$2.41 loss per share (vs US$3.35 loss in 1Q 2023)

BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

BeiGene, Ltd., Annual General Meeting, Jun 05, 2024

Co-Founder recently sold US$7.5m worth of stock

Co-Founder notifies of intention to sell stock

BeiGene, Ltd. to Report Q1, 2024 Results on May 11, 2024

BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

Co-Founder notifies of intention to sell stock

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

BeiGene, Ltd. Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

BeiGene, Ltd. to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024

BeiGene, Ltd. Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Full year 2023 earnings released: US$8.45 loss per share (vs US$19.43 loss in FY 2022)

BeiGene, Ltd. Announces Adults Living with Chronic Lymphocytic Leukemia in Ontario and Quebec Now Have Access, Through Public Reimbursement, to BRUKINSA® (Zanubrutinib)

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Now 21% undervalued after recent price drop

Beigene, Ltd. Announces Board Changes

Now 22% undervalued after recent price drop

Forecast to breakeven in 2026

BeiGene, Ltd. Announces FDA Approves Label Update for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

BeiGene, Ltd. Receives European Commission Approval for BRUKINSA®? (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Co-Founder notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 11%

Consensus EPS estimates upgraded to US$11.07 loss

Beigene, Ltd. Receives Positive Recommendation from Nice in U.K. for Adult Patients with Chronic Lymphocytic Leukemia

BeiGene, Ltd. Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeli

Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

Consensus EPS estimates fall by 18%

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

U.S. FDA Accepts Biologics License Application in First-Line Advanced ESCC

BeiGene, Ltd. Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA(R)

Beigene, Ltd. Announces Change of Chair of Audit Committee

New minor risk - Profitability

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$3.64 loss per share (vs US$5.51 loss in 2Q 2022)

Beigene Announces Positive CHMP Opinion for Tislelizumab as Treatment for Advanced or Metastatic ESCC

Beigene, Ltd. Announces FDA Acceptance of sNDA for Fifth Brukinsa(R) Indication

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?

BeiGene, Ltd. to Report First Half, 2023 Results on Aug 30, 2023

New minor risk - Shareholder dilution

Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

BeiGene Highlights Significant Brukinsa® (Zanubrutinib) Data at 17th International Conference on Malignant Lymphoma

Pharmacyclics LLC Files Complaint Against Beigene, Ltd. and Beigene USA, Inc

Now 20% undervalued after recent price drop

BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress

BeiGene, Ltd. Announces Approval of BRUKINSA (Zanubrutinib) by Health Canada for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia

BeiGene, Ltd. Announces Presentations At the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio

President recently sold US$1.8m worth of stock

President notifies of intention to sell stock

Consensus EPS estimates fall by 18%

Beigene, Ltd. Provides Update Regarding Recent Business Developments

First quarter 2023 earnings: EPS exceeds analyst expectations

Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)

A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)

Key Executive exercised options and sold US$15m worth of stock

CFO & Principal Accounting Officer notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

BeiGene Announces BRUKINSA Approved in the U.S. for Chronic Lymphocytic Leukemia

マネジメント基準チェック /24